Microcap Ledger Rezolute, Inc. $RZLT
Facts as of . Built from SEC filings and our own data. Small caps move fast; check the latest filings.
Snapshot
- Exchange
- Nasdaq Capital Market
- Sector
- Pharmaceutical Preparations
- Headquarters
- Redwood City, CA
- Fiscal year end
- June 30
- Shares outstanding
- 96,722,333 [10-K 2026-09-24]
What the company doesAI summary of filing
Rezolute, Inc. is a late-stage rare disease company developing therapies for hyperinsulinism-related hypoglycemia. The company's lead asset, ersodetug, is a human monoclonal antibody that binds to the insulin receptor to reduce excessive insulin activity; it is being evaluated in a Phase 3 trial for congenital hyperinsulinism (sunRIZE study) and a Phase 3 trial for tumor hyperinsulinism (upLIFT study), with results from sunRIZE announced in December 2025 that did not meet primary and key secondary endpoints, though the company observed improvements in continuous glucose monitoring endpoints. The company generates no reported revenue and maintains expanded access programs providing compassionate use of ersodetug to patients with various forms of hyperinsulinism who have refractory hypoglycemia. [10-K 2026-09-24]
Financial health
| Period | Revenue | Net income | Operating cash flow | Cash | Filing |
|---|---|---|---|---|---|
| FY ended Jun 2026 | — | −$77.59M | −$64.64M | $10.62M | [PRE 14A 2026-10-07] |
| FY ended Jun 2025 | — | −$74.41M | −$69.08M | $94.11M | [PRE 14A 2026-10-07] |
- Quarterly cash burn
- −$16.16M
- Cash runway Estimate
- ~2 months
Capital structure and dilution
| Date | Shares outstanding | Filing |
|---|---|---|
| 2024-11-05 | 57,943,066 | [10-Q 2024-11-07] |
| 2025-02-07 | 60,535,425 | [10-Q 2025-02-12] |
| 2025-05-09 | 85,519,318 | [10-Q 2025-05-13] |
| 2025-09-15 | 90,811,368 | [10-K 2025-09-17] |
| 2025-11-04 | 92,727,532 | [10-Q 2025-11-06] |
| 2026-02-09 | 95,697,685 | [10-Q 2026-02-12] |
| 2026-05-08 | 96,292,331 | [10-Q 2026-05-12] |
| 2026-09-21 | 96,722,333 | [10-K 2026-09-24] |
- Shelf registration
- S-3ASR filed 2025-12-05 [S-3ASR 2025-12-05]
Listing status
Current status: No Form 8-K Item 3.01 (listing notice) filings in the last 24 months, as of 2026-10-11.
Who owns it
| Date | Insider | Type | Shares | Price | Filing |
|---|---|---|---|---|---|
| 2026-09-02 | Karnawat Sunil Ratilal | other | 2,267 | $4.50 | [4 2026-09-03] |
| 2026-07-02 | Roberts Brian Kenneth | other | 3,062 | $4.99 | [4 2026-07-07] |
| 2026-07-02 | Elam Nevan C | other | 8,004 | $4.99 | [4 2026-07-07] |
| 2026-07-02 | Evans Daron | other | 3,062 | $4.99 | [4 2026-07-07] |
| 2026-03-30 | Evans Daron | buy | 10,000 | $2.85 | [4 2026-03-31] |
| 2026-03-02 | Roberts Brian Kenneth | other | 11,439 | $2.99 | [4 2026-03-04] |
| 2026-03-02 | Evans Daron | other | 11,438 | $2.99 | [4 2026-03-04] |
| 2026-03-02 | Elam Nevan C | other | 27,618 | $2.99 | [4 2026-03-04] |
Catalysts and calendar
| Date | Type | Title |
|---|---|---|
| 2026-10-07 | PRE 14A | Proxy statement |
| 2026-10-05 | 8-K | Regulation FD disclosure |
| 2026-09-24 | 10-K | Annual report |
| 2026-09-24 | 8-K | Results of operations |
| 2026-08-14 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2026-08-12 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2026-08-12 | 13G | Beneficial ownership report (5%+ holder) |
| 2026-06-02 | 8-K | Regulation FD disclosure |
| 2026-05-15 | 13G | Beneficial ownership report (5%+ holder) |
| 2026-05-12 | 10-Q | Quarterly report |
| 2026-05-12 | 8-K | Results of operations |
| 2026-05-11 | 13G/A | Beneficial ownership report (5%+ holder) |
Alerts for $RZLT
Email me when Rezolute, Inc. files an offering, gets a deficiency notice, or moves sharply.
Facts as of . Small caps move fast; check the latest filings.